Reducing barriers to the hepatitis C care cascade in prison via point‐of‐care RNA testing: a qualitative exploration of men in prison using an integrated framework
Open Access
- 12 February 2023
- Vol. 118 (6) , 1153-1160
Abstract
Background and Aims: Hepatitis C virus (HCV) is highly prevalent within the prison setting. Although HCV testing and treatment are available within prisons, system barriers can impede progress along the HCV care cascade for those who are incarcerated. The PIVOT intervention used a ‘one‐stop‐shop‘ model (i.e. point‐of‐care HCV RNA testing, Fibroscan‐based liver disease assessment and treatment) at a reception prison in New South Wales, Australia. This analysis sought to understand the role of point‐of‐care HCV RNA testing at intake in reducing barriers to the HCV care cascade within the male prison setting.Design and Setting: Qualitative analysis using semi‐structured interviews in a reception prison in Australia.Participants: Twenty‐four men enrolled in the PIVOT study; all participants had undergone HCV point‐of‐care testing in the intervention arm.Measurements: Høj's Integrated Framework informed this analysis.Findings: Participants widely expressed the view that point‐of‐care HCV RNA testing on entry was beneficial for care engagement. Point‐of‐care testing was perceived as timely (compared with standard pathology) and reduced opportunities for adjudication by correctional officers due to fewer clinic visits for testing and results. Adoption of routine opt‐out testing at prison intake was regarded as an important strategy for normalising HCV testing (and likely to increase pathways to treatment uptake) and fostered patient candidacy (i.e. self‐perceived eligibility to access care).Conclusion: Twenty‐four men in prison in New South Wales, Australia, who underwent opt‐out point‐of‐care HCV RNA testing on entry into prison, widely supported the programme as a means of overcoming barriers to HCV testing and treatment in the prison setting, as well as providing public health benefits through early detection of HCV infection among people entering into custody.Keywords
Funding Information
- National Health and Medical Research Council (APP1135247)
- AbbVie
- Cepheid
This publication has 43 references indexed in Scilit:
- Prison officers’ views about hepatitis C testing and treatment: a qualitative enquiryJournal of Clinical Nursing, 2017
- Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013The Lancet Infectious Diseases, 2016
- Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive studyCMAJ Open, 2016
- The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High?PLOS ONE, 2016
- Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detaineesThe Lancet, 2016
- Unlocking dimensions of social capital in the prison settingHealth & Justice, 2016
- Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United StatesAnnals of Internal Medicine, 2015
- A Descriptive Model of Patient Readiness, Motivators, and Hepatitis C Treatment Uptake among Australian PrisonersPLOS ONE, 2014
- Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysisClinical Infectious Diseases, 2013
- Negotiating access to medical treatment and the making of patient citizenship: the case of hepatitis C treatmentSociology of Health & Illness, 2013